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Neglected players: Tumor associated neutrophils involvement 
in chronic lymphocytic leukemia progression
Enrique Podaza and Denise Risnik
The old paradigm that establishes that neutrophils 
are just short half-life cells committed to kill bacteria in 
situ at early stages of infection is changing. Nowadays, 
there are plenty of reports that focus on neutrophils 
participation in tumor microenvironment giving rise to 
the so-called Tumor Associated Neutrophils (TANs). 
TANs appear to be very sensitive to microenvironmental 
signals increasing their lifespan and displaying 
remarkable phenotype plasticity and functionality. Even 
though defining a unique phenotype to classify TANs 
populations in cancer patients is complicated due to the 
lack of appropriate surface markers [1], their role as 
tumor promoters is supported by clinical observations that 
associate a higher neutrophil infiltrate at the tumor [2] and/
or a high neutrophil to lymphocyte ratio with poor outcome 
[3]. Most of the reports regarding TANs biology, both in 
murine models and patients, are in the context of solid 
tumors [1]. In 2016, our group described for the first time 
that neutrophils from Chronic Lymphocytic Leukemia 
(CLL) patients were prone to release extracellular traps 
(NETs) and that these structures promote leukemic cells 
activation and survival [4]. These findings encourage us to 
think about the possibility that leukemic cells could drive 
TANs differentiation in CLL. In 2018, we go further and 
reported that leukemic cells promote neutrophil survival 
through G/GM-CSF release and their IL-10/TGF-β-
driven reprogramming into CD16highCD62Ldim subset, 
which is capable of significantly suppress T-cell functions 
(proliferation and INFγ production) [5]. We aim directly 
at this subset, described in head and neck squamous 
cell carcinoma patients [6], given that these neutrophils 
exhibit a higher capacity to release NETs and are present 
in peripheral blood. We observed not only that leukemic 
cells were able to reprogram circulating neutrophils into 
this subset in vitro, but also that the proportion of these 
TANs was increased in CLL-patients.
A common feature of our work and that from 
Millrud et al is IL-8 involvement. We described that higher 
IL-8 plasmatic levels in CLL-patients were responsible 
of the increased NETs formation observed in vitro upon 
stimulation while Millrud reported that CD16highCD62Ldim 
neutrophils are sensitized to respond to IL-8 migrating 
rapidly to tumor tissues. 
It is known that higher plasmatic levels of IL-8 in 
CLL-patients [7] are related with poor prognosis but as we 
previously described [8] it is not a consequence of a direct 
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Figure 1: Schematic overview
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action of this chemokine on leukemic cells, since they are 
not able to detect nor produce it.
Although there are many cells capable of secreting 
IL-8, monocytes and macrophages have an exacerbated 
capacity to produce this chemokine. In CLL patients, 
monocytes are not only increased in number in the 
circulation, but they are also recruited to the lymphoid 
tissues by the leukemic cells through the secretion of 
CCL3 and CCL4, once there they differentiate into Nurse-
like cells (NLCs). In advanced stages of the disease, 
CD68+ myeloid cells (macrophage marker) number 
increases in the lymphoid tissues [9] as well as IL-8 
plasmatic levels, suggesting that these cells constitute the 
main source of IL-8 in CLL patients.
Considering all data described before, we propose 
that a possible link between NLC-derived IL-8 and CLL 
progression could be TANs differentiation. This idea is 
in part supported by the fact that NETs-like structures 
were observed in close contact to leukemic cells in spleen 
biopsies of CLL-patients [10] and for our own results 
that suggest an association between a high percentage of 
circulating CD16highCD62Ldim neutrophils and advance 
disease. Even though some pieces of this puzzle are still 
missing, we encourage the CLL-research community to 
put NLC-IL-8-TAN axis under the spotlight by addressing 
the percentage of circulating CD16highCD62Ldim in 
peripheral blood samples, since its presence could give us 
an insight of what is happening in lymphoid tissues. In 
addition, linking it to several clinical variables in larger 
patient’s cohorts could be helpful to confirm its value as a 
possible low-cost biomarker of CLL-progression (Figure 
1).
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